Sign Out
UserName
Profession Email
Profession Email
De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.
MIMS is a trusted, accurate and user-friendly medication information platform. Designed to empower both healthcare professionals and general public to support informed healthcare decisions, our leading drug directory provides clear, reliable information on prescription drugs, over-the-counter medications and other medical resources.
Don’t miss out on key updates in healthcare.
Continue with Google
Sign Up With Email
Already a member?
Sign In
